首页
>>
产品中心
>>
蛋白产品
>>
重组蛋白
>
Recombinant Human LR3 IGF-I Protein

Recombinant Human LR3 IGF-I Protein

产品编号

KRP683

别名

重组人LR3 IGF1蛋白,Long R3 IGF-I, LR3 Insulin-like growth factor I, Insulin-like growth factor 1, IGF-I LR3, IGFI,

规格
  • 100ug
  • 500ug
  • 1mg
产品介绍
Alias重组人LR3 IGF1蛋白,Long R3 IGF-I, LR3 Insulin-like growth factor I, Insulin-like growth factor 1, IGF-I LR3, IGFI,
Catalog NumberKRP683
Molecular NameIGF1 
SpeciesHuman
HostE.coli
Size100ug,500ug,1mg
Purity >97%, determined by SDS-PAGE.
Concentration联系销售经理获得最新批次的浓度
PurificationAffinity Purification
Endotoxin<0.01 EU/μg, determined by LAL method.
BackgroundIGF-1的一种长效类似物,通过氨基酸替换和N端延伸肽(R3)降低其与结合蛋白(IGFBP)的亲和力,从而增强其生物活性和稳定性,主要用于科学研究。
ApplicationWB, ELISA
Predicted Molecular Weight9 kDa
ReconstitutionIt is recommended that the lyophilized human LR3 IGF-I protein be dissolved in 100 mM Acetic Acid at a concentration of 100-200 μg/mL for further dilution as the working concentration.
Storage ConditionSamples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Avoid repeated freeze-thaw cycles.
Shipping ConditionThis product is shipped on ice packs or dry ice.
Stability Repeated freezing and thawing is not recommended.
Molecular Weight8 kDa,
Uniprot IDP05019
References1. Philippou, A. et al. (2007) In Vivo 21:45. 2. Sandberg-Nordqvist, A.C. et al. (1992) Brain Res. Mol. Brain Res. 12:275. 3. Berryman, D.E. et al. (2013) Nat. Rev. Endocrinol. 9:346. 4. Guvakova, M.A. (2007) Int. J. Biochem. Cell Biol. 39:890. 5. Sadagurski, M. and M.F. White (2013) Endocrinol. Metab. Clin. North Am. 42:127. 6. Clemmons, D.R. (2006) Curr. Opin. Pharmacol. 6:620. 7. Bluher, S. et al. (2005) Best Pract. Res. Clin. Endocrinol. Metab. 19:577. 8. Garcia-Segura, L.M. et al. (2006) Neuroendocrinology 84:275. 9. Malemud, C.J. (2007) Clin. Chim. Acta 375:10. 10. Ling, P.R. et al. (1995) Am. J. Clin. Nutr. 61:116. 11. Sheng, M.H. et al. (2014) J. Bone Metab. 21:41. 12. Samani, A.A. et al. (2007) Endocrine Rev. 28:20. 13. Gallagher, E.J. et al. (2010) Endocr. Pract. 16:864. 14. LeRoith, D. and S. Yakar (2007) Nat. Clin. Pract. Endocrinol. Metab. 3:302. 15. Denley, A. et al. (2005) Cytokine Growth Factor Rev. 16:421. 16. Duan, C. and Q. Xu (2005) Gen. Comp. Endocrinol. 142:44. 17. Francis, G.L. et al. (1992) J. Mol. Endocrinol. 8:213. 18. Voorhamme, D. and C.A. Yandell (2006) Mol. Biotechnol. 34:201. 19. Tomas, F.M. et al. (1993) Biochem. J. 291:781. 20. Tomas, F.M. et al. (1996) J. Endocrinol. 150:77. 21. Tomas, F.M. et al. (1997) J. Endocrinol. 155:377. 22. von der Thüsen, J.H. et al. (2011) Am. J. Pathol. 178:924
Function重组人长效IGF-1变体(LR3 IGF-1),具有增强的稳定性与生物活性。适用于长效细胞增殖研究、肌肉再生实验及代谢疾病相关机制探索。
Product Declaration该产品仅供科研使用,不可直接用于人体或注射。
Temperature RangeStore the product under sterile conditions after opening at -80℃ for 12 months. Store the lyophilized powder at -27℃. Avoid repeated freeze-thaw cycles.
Product Full NameRecombinant Human LR3 IGF-I Protein
TargetLR3 IGF-I
FAQ
  • LR3 IGF-1和普通IGF-1有什么区别?

    它是IGF-1的类似物,与IGF-1受体结合亲和力更强,且在体内的半衰期显著延长。

  • 在培养中何时选择使用它?

    当需要更强劲、更持久的促生长和抗凋亡信号时使用,例如在高密度干细胞扩增或细胞处于应激条件时。

登录

还没有账号?立即注册

注册

已有账号?立即登录

立即询价